Form 4: Inovio Pharmaceuticals Director Simon X. Benito Reports Stock Transaction
SEC Form 4 Filing
Director Simon X. Benito reports the vesting and acquisition of 2,166 shares of Inovio Pharmaceuticals common stock on May 15, 2024, related to restricted stock units.
Summary
- On May 15, 2024, Simon X. Benito, a director of Inovio Pharmaceuticals, acquired 2,166 shares of common stock.
- This acquisition resulted from the vesting of restricted stock units.
- The restricted stock units vested 100% on May 15, 2024.
- The reported transaction gives effect to a 1-for-12 reverse stock split that Inovio Pharmaceuticals implemented on January 24, 2024.
- Following the transaction, Benito directly owns 10,024 shares of Inovio Pharmaceuticals.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing a stock transaction by a company director, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities, allowing investors to monitor the actions of company insiders.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding the director's holdings and aligns his interests with theirs.
Key Dates
| Date | Description |
|---|---|
| January 24, 2024 | Inovio Pharmaceuticals effected a 1-for-12 reverse stock split. |
| May 15, 2024 | Restricted stock units vested 100%. |
| May 15, 2024 | Simon X. Benito acquired 2,166 shares of common stock. |
| May 16, 2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.